Among these, glucagon-like peptide-1 (GLP-1) receptor agonists, and more recently, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have emerged as powerful tools in the armamentarium against obesity. This evidence concerns the gene GCG and obesity disorder.